Anonymous
Guest
Anonymous
Guest
Pricing and marketing will be what kills this drug. $100 a dose isn't going to attract many takers. I know the folks in marketing think they have developed a strategy that will demonstrate the "value" of this product and overcome the ridiculous price but at the end of the day Merck has shot themselves in the foot by overestimating how much they can gouge the hospitals for.
The data wasn't "played with". They just thoroughly screwed up the data collection and analysis portion. Which is even worse than altering data these days. I've heard of tons of companies altering data. I've never even heard of a company screwing up the data collection and analysis process. For a product that was limping along with a poor marketing strategy and 10 years of delays it has attached such a bad taste that clinicians now think there has to be something wrong with the product.
Basically it just shows how inept Merck is from top to bottom. In 25 years I've never seen a company go from a top notch, respected company to an absolute joke and one that will be fortunate to remain functional over the next few years.
Please do us a really big favor - go to sleep